DoD Funds Production of More Life-Saving Medicine for Use After Nerve Agent Exposure

Home / Articles / External Government

JPM CBRN Medical
JPM CBRN Medical

January 10, 2023 | Originally published by Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense on December 22, 2022

FORT DETRICK, Md. – December 22, 2022 – The Defense Department’s office responsible for acquiring medical countermeasures against chemical, biological, radiological, and nuclear (CBRN) threats has awarded an agreement for the production of more life-saving nerve agent exposure treatments. The Joint Project Manager for CBRN Medical (JPM CBRN Medical) awarded a follow-on other transaction authority production agreement to Rafa Laboratories, Ltd. (Rafa) to manufacture and deliver 10mg midazolam injection autoinjectors to the Joint Force beginning December 2022.

The midazolam injection autoinjector is indicated to treat prolonged seizures in adults, which can occur after exposure to a nerve agent. This new Advanced Anticonvulsant System (AAS) improves upon, and will eventually replace, the currently fielded Convulsant Antidote for Nerve Agent (CANA) diazepam autoinjector. Fielding the midazolam injection autoinjector gives the Warfighter and the nation access to a life-saving medical countermeasure in CBRN environments.

Focus Areas

Want to find out more about this topic?

Request a FREE Technical Inquiry!